Trial Profile

A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; ACP 319 (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma
Focus Adverse reactions; Proof of concept
Sponsors Acerta Pharma

Most Recent Events

19 Jan 2024 Planned End Date changed from 31 Dec 2025 to 1 Apr 2026.
25 Mar 2021 Planned End Date changed from 1 Mar 2020 to 31 Dec 2025.
20 Feb 2019 Planned End Date changed from 1 Nov 2017 to 1 Mar 2020.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com